Filing Flows › Omada Health (OMDA) › Q1 2026
Omada Health (OMDA) Q1 2026 earnings results (first quarter 2026)
10-Q filed May 8, 2026
Omada Health (OMDA) reported revenue of $78.0M for the first quarter 2026 (Q1 2026), +42% from a year earlier and +3% from the quarter before. Operating margin was -6.1%, net loss $3.0M (3.8% of revenue).
Omada Health, Q1 2026: revenue $78.0M (+42% year over year), operating margin -6.1%, net loss $3.0M, operating cash flow −$11.8M. The chart follows the revenue to costs, profit and cash.
| Q1 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $78.0M | +3% | +42% |
| Operating profit | −$4.8M | -246% | — |
| Net earnings | −$3.0M | -158% | — |
| Operating cash flow | −$11.8M | -155% | — |
What changed
Revenue was $78.0M in Q1 2026, up 42% year over year and up 3% from the previous quarter. Services was the largest line at 89% of revenue. Services added $20.1M year over year (up 41%), 87% of the total change.
Gross margin was 62.4%, up 4.3 points from a year earlier. Operating costs exceeded revenue by $4.8M, an operating margin of -6.1%. Operating expenses grew 33% against revenue growth of 42%. The fastest-growing cost line was Research & development (+44%). The quarter ended with a net loss of $3.0M, after a profit of $5.2M the previous quarter. Non-operating items added $1.8M, -61% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$11.8M. Non-cash charges added back $1.5M of depreciation and amortization and $4.2M of share-based compensation. Working capital and other items used $14.6M. Capital expenditures of $78K exceeded it, leaving free cash flow of −$11.9M.
Questions
What was Omada Health's revenue in the first quarter 2026?
Omada Health (OMDA) reported revenue of $78.0M for the first quarter 2026 (Q1 2026), +42% from a year earlier and +3% from the quarter before.
Was Omada Health profitable in the first quarter 2026?
Operating loss was $4.8M (-6.1% of revenue) and net loss $3.0M.
Source: Omada Health 10-Q on SEC EDGAR.